We should stop acting as if Big Pharma is the big villain in American health care
We are the problem when we would rather take the injection or the pill than make the lifestyle change. I am fortunate that I ...
BioSpace11d
This Might Be a Moot Point but the FDA’s Priority Review Vouchers Need Transparency
While Congress is renewing the priority review voucher program for rare pediatric diseases, the FDA should be required to ...
Benzinga.com7d
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below provides a snapshot of their recent ratings ...
Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review
ATyr Pharma shares gained after its experimental treatment for an inflammatory lung disease passed another safety checkpoint. The stock rose 8% to $3.34 on Friday. It has more than doubled in the past ...
BioPharma Dive11d
Roche launches new Boston center; NIH centralizes peer review
The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio, Bayer’s gene therapy ...
Nasdaq6d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal ...
Business Insider12d
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq ... “The positive outcome from this fourth DSMB review for EFZO-FIT™ further reinforces our confidence in the favorable ...